These 10 medical device companies spent the largest portion of their budgets on research and development. Here’s a look at what they produced. Each year, Medical Design & Outsourcing compiles a list of the top 100 medical device companies across the globe and ranks the companies based on annual revenue for the most recent fiscal year. We […]
AtriCure wins expanded indications for AtriClip LAA
AtriCure (NSDQ:ATRC) said today that it won expanded 510(k) clearances from the FDA for its AtriClip left atrial appendage device. The new indications cover a change from occlusion of the LAA to exclusion and adding electrical isolation as a claim, Mason, Ohio-based AtriCure said. AtriClip excludes the LAA and causes its tissue to die from loss […]
AtriCure closes $300m SentreHeart buyout
AtriCure (NSDQ:ATRC) said yesterday that it closed the $300 million buyout of SentreHeart and its Lariat left atrial appendage closure device. The offer included $40 million in up-front cash and stock, plus $140 million in clinical and regulatory milestones and $120 million in reimbursement milestones, all payable in cash and stock, Mason, Ohio-based AtriCure said when the […]
AtriCure offers $300m for SentreHeart
AtriCure (NSDQ:ATRC) said today that it put up a $300 million offer for SentreHeart and its Lariat left atrial appendage closure device. Redwood City, Calif.-based SentreHeart has enrolled 535 patients in the Amaze trial comparing Lariat and pulmonary vein isolation with PVI alone in treating atrial fibrillation. Today AtriCure said it expects the study tor each […]
AtriCure shares steady on Street-beating Q1
Shares in AtriCure (NSDQ:ATRC) are steady in after hours trading today after the medical device maker posted first quarter earnings for 2019 that beat expectations on Wall Street. The Mason, Ohio-based company posted losses of approximately $5.6 million, or 15¢ per share, on sales of approximately $54 million for the three months ended March 31, seeing […]
AtriCure restarts DEEP dual-procedure clinical trial
AtriCure (NSDQ:ATRC) said today that it restarted enrollment in its DEEP clinical trial, touting that the first newly added patient in the trial has already been treated. The Mason, Ohio-based company’s DEEP trial is an FDA investigational device exempt study exploring the safety and efficacy of the company’s dual epicardial and endocardial procedure intended to treat […]
AtriCure shares dip despite Q4 earnings beat
Shares in AtriCure (NSDQ:ATRC) have fallen slightly today despite the medical device maker posting fourth quarter earnings that topped expectations on Wall Street. The Mason, Ohio-based company posted losses of $3.4 million, or 9¢ per share, on sales of $52.9 million for the three months ended December 31, seeing losses grow 32.9% while sales grew 14.8% […]
AtriCure launches CryoIce CryoSphere probe
AtriCure (NSDQ:ATRC) today launched its CryoIce CryoSphere probe in the U.S. The Mason, Ohio-based company’s CryoSphere probe is designed to block pain by temporarily ablating peripheral nerves. The device features a bendable distal shaft and an ergonomic handle that enables cardiac, thoracic and general surgeons to easily target peripheral nerves. ArtiCure’s CryoSphere technology uses a freezing […]
AtriCure launches CryoIce persistent AF ablation trial
AtriCure (NSDQ:ATRC) said today that it launched a new FDA investigational device exemption cleared trial of its CryoIce system exploring its use in treating persistent atrial fibrillation during concomitant open-chested cardiac surgery. The first patient in the trial has already been treated, the Mason, Ohio-based company said. The initial procedure took place at Takoma Park, Md.’s […]
10 of the best performing medical device stocks of 2018
Updated Jan. 8, 2019 Medical device company stocks are not looking as rosy as they did two months ago, but the medtech industry still appears to be resisting the overall downward trend in stock markets, according to a Medical Design & Outsourcinganalysis. More than half of the roughly 100 largest medical device companies in the world […]
AtriCure falls despite solid Q4, 2018 prelims | Wall Street Beat
AtriCure (NSDQ:ATRC) shares took a fall today despite preliminary results for the fourth quarter and 2018 that topped estimates. The Mason, Ohio-based cardiac implant maker said it expects to post Q4 sales of $52.9 million and 2018 sales of $201.6 million, beating the consensus estimatyes on Wall Street for both periods. “We are pleased with our […]
- 1
- 2
- 3
- …
- 10
- Next Page »
MassDevice Network
@MassDevice
LinkedIn
YouTube